Ref: Protocol: 0063-17
A global, multicenter, three arms, open-label randomized study to evaluate the e?cacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.
Protocol Title :
‘A Prospective, Randomized, Multicentre, Comparative, open-label, Parallel study to evaluate the E?cacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC-3255; Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine (Kadcyla@, a product of Roche) in HER2- Positive Metastatic Breast Cancer Patients.
A randomized, double-blind, placebo-controlled, phase III study evaluating the e?cacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as ?rst line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1).
"A pilot study (Phase II Trial )of Ge?tinib With Pemetrexed as First-Line Therapy in Patients With Advanced Non-squamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations positive patients." (Investigator Initiative Trial).
Protocol Number: WOC/AMS/CT-44/14
"A surveillance study on the antibiotic susceptibility pattern of bacterial isolates collected from patients at various Indian tertiary care hospitals"
A pilot study (Phase II Trial) of Cetuximab with Afatinib as First-Line Therapy in patients With Advanced Non-Sequamous Non-Samall-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Multations positive patients. - PI Dr. Naresh Somani
A pilot study (Phase II Trial ) of Gefitinib/Afatinib with pemetrexed as First-Line therapy in Patients with advanced Non-squamous Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh Somani
A pilot study (Phase II Trial ) of Nivolumab with Pemetrexed as Palliative Chemotherapy in Patients with advanced Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh Somani